Table 2. Details of Included RCTs Comparing NAC with SA in Our Meta-Analysis (Part B).

Authors	Main inclusion criteria	Regimen and administration	Median Follow-up (months)	Available outcomes
Shchepotin et al [41]	Gastric carcinoma	Intra-arterial	NR	OS
Kang et al [42]	Gastric adenocarcinoma	PEF (DDP/epirubicin/5-FU)	>36	R0 resection, tumor stage at resection
Kobayashi et al [43]	Resectable advanced gastric cancer; ≤75 years	5′-DFUR: oral, ≥610 mg/m2/d×10 d	NR	OS, R0 resection, tumor stage at resection (only T stage), safety of NAC
Wang et al [44]	Resectable gastric cancer	FPLC: oral	60	5-year survival, perioperative morbidity
Hartgrink et al [45]	Resectable gastric adenocarcinoma; >cT1 M0; PS 0–2; ≤75 years	FAMTX: intravenous; methotrexate 1500 mg/m2, 5-FU 1500 mg/m2, leucovorin 30 mg/6 h×2 d, doxorubicin 30 mg/m2; 4 courses	83	OS, R0 resection, tumor stage at resection, safety of NAC, perioperative morbidity
Nio et al [46]	Resectable gastric cancer; PS 0–3	UFT (tegafur/uracil): oral, FT: 7 mg/kg/d×21 d	83	OS, R0 resection, tumor stage at resection, safety of NAC, perioperative morbidity
Zhao et al [47]	Gastric adenocarcinoma, Karnofsky's scale >90, ≤70 years	5′-DFUR (oral, 800–1200 mg/d) or DDP/5-FU (intravenous, 500 mg 5-FU+200 mg/d CF)×3–5 d	NR	OS, R0 resection, tumor stage at resection, perioperative morbidity and mortality
Imano et al [48]	Resectable advanced gastric cancer; <75 years; PS 0–1	5-FU (330 mg/m2/d×3 d) or DDP (18 mg/m2) or 5-FU+DDP: intravenous	NR	OS, R0 resection, tumor stage at resection, safety of NAC, perioperative morbidity
Schuhmacher et al [49]	Locally advanced resectable gastric adenocarcinoma, stages III and IV; cT3/4 M0/1; PS 0–1; 18–70 years	DDP (50 mg/m2/d×3 d), d-L-folinic acid (500 mg/m2/d×6 d), 5-FU (2000 mg/m2/d×6 d); 2 courses; intravenous	53	OS, progression-free survival (PFS), R0 resection, tumor stage at resection, safety of NAC, perioperative morbidity

RCTs, randomized controlled trials; NAC, neoadjuvant chemotherapy; SA, surgery alone; NR, not reported; OS, overall survival; PS, performance status (ECOG/WHO); 5-FU, 5-fluorouracil; 5′-DFUR, 5′-Deoxy-5-fluorouridine; DDP, cisplatin; FPLC, fluorouracil polyphase liposome composita pro orale, consisting of 5-FU, oleic acid, ginseng polysaccharides, bean phospholipid and cholesterol; R0 resection, presence of tumor-free resection margin.